NCT06610734 Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
| NCT ID | NCT06610734 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Sichuan University |
| Condition | Small Cell Lung Cancer Extensive Stage |
| Study Type | INTERVENTIONAL |
| Enrollment | 202 participants |
| Start Date | 2024-12-23 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 202 participants in total. It began in 2024-12-23 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined with Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Eligibility Criteria
Inclusion Criteria: * Participants aged 18 to 75 years, regardless of gender; * ECOG Performance Status (PS) score of 0-1; * Expected survival duration of no less than 8 weeks; * Histologically or cytologically confirmed extensive small cell lung cancer (according to the VALG staging system); * Subjects must not have received systemic therapy or radical radiotherapy for extensive SCLC prior to enrollment. Exclusion Criteria: * Tissue classifications of mixed small cell lung cancer and non-small cell lung cancer; * Patients who have undergone major surgical procedures within 28 days prior to the initial administration of the study drug, or those planning to undergo major surgery during the study period (as determined by the investigator); * Receipt of live attenuated vaccines within 28 days before the first dose or planned for the duration of the study; * Participation in another clinical trial within 28 days preceding initial dosing, involving any experimental agents; * History of receiving chest radiotherapy or plans for intensive chest radiotherapy prior to systemic therapy; * Any previous T-cell co-stimulation or immune checkpoint therapies administered; * Documented history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\"
Contact & Investigator
You Lu
PRINCIPAL INVESTIGATOR
West China Hospital
Frequently Asked Questions
Who can join the NCT06610734 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Small Cell Lung Cancer Extensive Stage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06610734 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06610734 currently recruiting?
Yes, NCT06610734 is actively recruiting participants. Contact the research team at radyoulu@hotmail.com for enrollment information.
Where is the NCT06610734 trial being conducted?
This trial is being conducted at Sichuan, China.
Who is sponsoring the NCT06610734 clinical trial?
NCT06610734 is sponsored by Sichuan University. The principal investigator is You Lu at West China Hospital. The trial plans to enroll 202 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.